IVPROvED RELIABILITY: Allows delivery of cell lines into mice hosting an intact immune system that accurately recapitula
T048
METHOD FOR GENERATING A NEW PANEL OF TRANSPLANTABLE MOUSE LUNG CANCER CELL LINES
CONTEXT
TECHNOLOGY SUMMARY
Current lung cancer research and drug discovery utilizes costly human lung cancer cell lines with defined mutations that can only be delivered in immunodeficient mice so they cannot reject human cells, which yield to inconsistent results given that cancer develops in humans and animals with an intact immune system.
This technology is a method for generating an unlimited pool of a new panel of mouse lung cancer cell lines.
Thanks to this method, it is possible to develop a panel of transplantable mouse lung cancer cell lines with a defined mutation status to be used in high-throughput in vitro drug discovery and in vivo preclinical studies in immunosufficient mice.
Compared with the currently used human cell lines, mouse cell lines are less expensive and improve the reliability of scientific results since can be transplantable to mice with an intact immune system that accurately recapitulate most human cancer hallmarks and therefore allow the acceleration of research.
BENEFITS
This method allows the generation of an unlimited pool of such lines from various strains of mice.
Improved reliability: Allows delivery of cell lines
APPLICATIONS
Faster
The cell lines developed with this method could be useful for different applications:
Lung Cancer Research Drug discovery In vivo preclinical studies Biomedicine Disease detection and assessment
into mice hosting an intact immune system that accurately recapitulate most human cancer hallmarks which leads to more reliable scientific results.
research: Lung cancer research, in vitro drug discovery and in vivo preclinical studies research can be accelerated by simplifying gene and drug discovery and in vitro and in vivo drug/compound testing.
Less
expensive: Than the costly human lung cancer cell lines that are currently used. Moreover, improved results reliability and a simplified and faster research decreases the overall costs of research development.
THE KNOWLEDGE AGENTS ALLIANCE CONFIDENTIAL 1
T048
METHOD FOR GENERATING A NEW PANEL OF TRANSPLANTABLE MOUSE LUNG CANCER CELL LINES IP STATUS Patent in progress.
TECHNOLOGY READINESS LEVEL & TIME TO MARKET This methodology has been fully developed and tested. In particular, a mouse lung cancer cell panel with a defined mutation status has been developed and the methodology to do so (in vitro derivation, genetic manipulation and unlimited expansion) simplified.
KEYWORDS ORGANIZATION PROFILE This technology belongs to a relevant European public university.
lung cancer
cell line
immunologically compatible
mouse model
immune competent
carcinogene
BUSINESS OPPORTUNITY Technology transfer via IP licensing /patent transference.
CONTACT
Elisenda Casanelles commercialisation responsible
[email protected] +34 93 266 71 38
THE KNOWLEDGE AGENTS ALLIANCE CONFIDENTIAL 2
